<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml">
   <article xmlns="" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
      <head>
         <style type="text/css"> 		 
            	    table {background : #ffffdd;}
            		 	tr {background : #ddddff; padding : 1px;}
            			
         </style>
         <span class="citation_publisher">Hindawi Publishing Corporation</span>
         <h2 class="citation-title">Pseudohypoaldosteronism in a Neonate Presenting as Life-Threatening Hyperkalemia</h2>
         <span class="doi">10.1155/2016/6384697</span>
         <div class="contrib-group">contrib: 
            	  CONT
            	  
            <span class="citation_author">Najya A. Attia</span>
            <span class="citation_author_institution_ref">1</span>
            <span class="citation_author">Yousef I. Marzouk</span>
            <span class="citation_author_institution_ref">2</span>
         </div>
         <span class="email">[attiana@ngha.med.sa]</span>
         <span class="conflict">[]</span>
         <span class="contribs">[]</span>
         <span class="citation_pubdate">[2016-1-19]</span>
         <span class="citation_copyright">[Copyright 2016: ]</span>
         <span class="citation_licence">[Licence This is an open access article distributed under the Creative Commons Attribution
            License, which permits unrestricted use, distribution, and reproduction in any medium,
            provided the original work is properly cited.]
         </span>
         <span class="citation_funding">[]</span>
         <span class="citation_pagecount">[]</span>
         <span class="citation_data">[]</span>
      </head>
      <div id="abstract" tag="abstract">
         <h2>Abstract</h2>
         <p>
            <i>Context</i>. Pseudohypoaldosteronism type 1 (PHA1) is a life-threatening disease that causes
            severe hyperkalemia and cardiac arrest if not treated appropriately or if diagnosis
            is missed.
            <i> Objective.</i> To report a case of a newborn with vomiting and lethargy, ultimately diagnosed with
            pseudohypoaldosteronism.
            <i> Patient.</i> This case presented to the ED at an age of 14 days in hypovolemic shock. There was
            a family history of sudden infant death, her sister who was diagnosed with CAH and
            passed away at 3 months of age despite regular hormone replacement. Our patient had
            cardiac arrest in ED, due to hyperkalemia; while receiving fluid boluses, cardiopulmonary
            resuscitation was initiated. After stabilization, diagnostic workup demonstrated persistently
            low sodium, acidosis, and high potassium, which required peritoneal dialysis. Based
            on these findings, the patient was diagnosed with CAH. It turned out later that the
            patient had PHA1. Two years later, the patient had a new sibling with the same disease
            diagnosed at birth and started immediately on treatment without any complication.
            <i> Conclusions and Outcome.</i> This case highlights the significant diagnostic and therapeutic challenges in treating
            children with PHA1. Adrenal crisis is not always CAH; delayed diagnosis can lead to
            complication and even death. The presence of high plasma renin activity, aldosterone,
            and cortisol, along with the presence of hyponatremia and hyperkalemia, established
            the diagnosis of PHA type 1 and ruled out CAH.
         </p>
      </div>
      <div tagxxx="sec">
         <title>1. Background</title>
         <p>Pseudohypoaldosteronism (PHA) type 1 is a rare hereditary disorder caused by resistance
            to the aldosterone action. It is characterized by hyperkalemia, hyponatremia, metabolic
            acidosis, and high plasma aldosterone and renin concentrations [
            <span ref-type="bibr" rid="B1">
               <sup>
                  <a href="#B1">1</a>
               </sup>
            </span>]. PHA1 is further classified into renal (AD) and systemic (AR) [
            <span ref-type="bibr" rid="B2">
               <sup>
                  <a href="#B2">2</a>
               </sup>
            </span>]. Renal PHA1 is an autosomal dominant (AD) disorder with heterogeneous mutations
            on the gene coding for the aldosterone receptor [
            <span ref-type="bibr" rid="B3">
               <sup>
                  <a href="#B3">3</a>
               </sup>
            </span>], in which salt loss is restricted to the kidney. In contrast, systemic PHA1 has
            an autosomal recessive (AR) pattern of inheritance caused by loss-of-function mutation
            of the epithelial sodium channel (ENaC) [
            <span ref-type="bibr" rid="B4">
               <sup>
                  <a href="#B4">4</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B5">
               <sup>
                  <a href="#B5">5</a>
               </sup>
            </span>]; it is characterized by generalized salt loss in many organs, including the lung,
            kidney, colon, and sweat and salivary glands [
            <span ref-type="bibr" rid="B6">
               <sup>
                  <a href="#B6">6</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>].
         </p>
         <p>PHA1 usually presents in the neonatal period with hypovolemia, hyponatremia, hyperkalemia,
            and metabolic acidosis [
            <span ref-type="bibr" rid="B8">
               <sup>
                  <a href="#B8">8</a>
               </sup>
            </span>–
            <span ref-type="bibr" rid="B11">
               <sup>
                  <a href="#B11">11</a>
               </sup>
            </span>]. Its generalized presentation and lack of specific clinical features, in addition
            to the rarity of the disease, usually results in delayed diagnosis and an increased
            chance of mortality. Salt-wasting forms of congenital adrenal hyperplasia (CAH) are
            more common than PHA1 but have a similar presentation, such that health providers
            think of CAH first and start the patient on hydrocortisone and fludrocortisone, which
            are not effective in managing PHA1. Such incorrect management not only delays diagnosis
            but also complicates the case and can increase mortality.
         </p>
         <p>We present the case of a 14-day-old baby girl who presented to the emergency department
            (ED) with life-threatening hyperkalemia. She was treated for CAH but did not respond
            to treatment, and it was found that the hyperkalemia was due to PHA1 rather than CAH.
            The patient ultimately required peritoneal dialysis to control her hyperkalemia.
         </p>
      </div>
      <div tagxxx="sec">
         <title>2. Clinical Case</title>
         <p>The patient presented to the ED at the age of 14 days in hypovolemic shock. She was
            the second child of consanguineous parents and had a birth weight of 2.9 kg.
         </p>
         <p>There was a family history of sudden infant death. A female sibling died at 3 months
            of age after being diagnosed with CAH and receiving appropriate glucocorticoid and
            mineralocorticoid replacement.
         </p>
         <p>Our patient had cardiac arrest in the ED while receiving fluid boluses; the cardiac
            monitor showed peaked T waves and wide QRS complex, indicating hyperkalemia. Cardiopulmonary
            resuscitation was initiated, intubation was performed, and the patient was immediately
            started on hyperkalemia management, including intravenous calcium gluconate, nebulized
            salbutamol, insulin, and glucose infusion, intravenous sodium bicarbonate, and oral
            calcium resonium (potassium binding resin).
         </p>
         <p>Initial laboratory findings showed hyperkalemia (8.61 mmol/L), hyponatremia (122 mmol/L),
            and acidosis (arterial pH = 6.9; serum bicarbonate = 4.7 mmol/L). Intravenous sodium
            bicarbonate was given to improve acidosis and hyperkalemia; after three courses of
            nebulized salbutamol, insulin, and glucose infusion, the potassium level began to
            decline (6.73 mmol/L) and the patient was admitted to the pediatric intensive care
            unit (PICU).
         </p>
         <p>We considered adrenal crisis due to CAH in view of the patient's hyperkalemia, hyponatremia,
            acidosis, and family history of CAH with consanguineous parents. Blood was extracted
            for cortisol, adrenocorticotropic hormone (ACTH), renin, and aldosterone; then, the
            patient was started on hydrocortisone and fludrocortisone as a suspected case of CAH.
            The patient was not responding to treatment; her potassium fell to 6.52 mmol/L before
            rising again to 9.24 mmol/L and becoming refractory. The patient had cardiac arrest
            again and was resuscitated. Emergency peritoneal dialysis was initiated, after which
            the potassium level began to decline. 
            <span ref-type="table" rid="tab1">
               <a href="#tab1"> Table 1</a>
            </span> summarizes laboratory findings before and after initiation of peritoneal dialysis.
            
            <span ref-type="table" rid="tab2">
               <a href="#tab2"> Table 2</a>
            </span> shows the results of the hormonal studies. These findings ruled out CAH as the cause
            for the infant's physiologic collapse and hyperkalemia. The diagnosis of PHA type
            1 was assigned based on the elevated renin and aldosterone levels.
         </p>
         <p>Hydrocortisone and fludrocortisone were discontinued. The patient initially required
            parenteral sodium chloride and sodium bicarbonate, but subsequently oral sodium chloride
            and sodium bicarbonate were initiated. Oral calcium resonium was continued at a dosage
            of about 1-2 g/kg/day, and the potassium level was kept under check with adjustment
            to dosage according to the potassium level. The baby was discharged after her potassium
            and sodium levels and acidosis were corrected and found to be stable.
         </p>
         <p>Following her initial presentation, the child developed a skin rash diagnosed as eczema.
            She was admitted once when she developed gastroenteritis with severe dehydration.
            Management included intravenous sodium chloride, sodium bicarbonate, and treatment
            of hyperkalemia. Outpatient treatment included oral sodium chloride, sodium bicarbonate,
            and calcium resonium. The child is now 7 years old and has normal growth and development.
            A female sibling born when our patient was 3 years old had biochemical evidence of
            PHA type 1. Therapy was initiated to prevent a similar crisis.
         </p>
      </div>
      <div tagxxx="sec">
         <title>3. Discussion</title>
         <p>Aldosterone is a steroid hormone that regulates sodium and potassium homeostasis;
            it acts primarily on epithelial cells in the renal collecting ducts [
            <span ref-type="bibr" rid="B8">
               <sup>
                  <a href="#B8">8</a>
               </sup>
            </span>]. Aldosterone crosses the epithelial cell membrane and binds to the mineralocorticoid
            receptor (MR), which acts as a ligand-dependent transcription factor in target tissues,
            thereby promoting gene signaling [
            <span ref-type="bibr" rid="B9">
               <sup>
                  <a href="#B9">9</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B10">
               <sup>
                  <a href="#B10">10</a>
               </sup>
            </span>]. Transcription of signaling factors enhances sodium transport into the epithelial
            cell, which is then actively removed from the cell by the sodium-potassium ATPase
            on the basolateral membrane of the cell [
            <span ref-type="bibr" rid="B11">
               <sup>
                  <a href="#B11">11</a>
               </sup>
            </span>]. Inactivating mutations of the gene encoding the aldosterone receptor cause renal
            PHA type 1, while systemic PHA type 1 is caused by inactivating mutations of the ENaC
            subunit genes [
            <span ref-type="bibr" rid="B4">
               <sup>
                  <a href="#B4">4</a>
               </sup>
            </span>, 
            <span ref-type="bibr" rid="B5">
               <sup>
                  <a href="#B5">5</a>
               </sup>
            </span>].
         </p>
         <p>The clinical spectrum of renal PHA varies widely from asymptomatic patients diagnosed
            only with elevated renin and aldosterone to patients presenting with a salt-wasting
            crisis. More than 50 different mutations have been described but there are no genotype/phenotype
            correlations. The generalized form of PHA type 1 leads to salt loss from organs expressing
            ENaC, including the kidneys, salivary and sweat glands, and the colon. Patients typically
            present shortly after birth with electrolyte findings mimicking adrenal crisis. It
            is usually severe and persists into adulthood.
         </p>
         <p>The electrolyte abnormalities of hyponatremia, hyperkalemia, and metabolic acidosis
            are similar in CAH and PHA. However, in contrast to CAH, serum cortisol and aldosterone
            levels are elevated in PHA indicating normal glucocorticoid production and resistance
            to aldosterone activity. The patient presented here clinically fits the picture of
            systemic PHA1 with severe refractory hyperkalemia requiring peritoneal dialysis at
            diagnosis and continued requirement for salt supplementation. Systemic PHA1 is also
            associated with other clinical features including skin changes [
            <span ref-type="bibr" rid="B9">
               <sup>
                  <a href="#B9">9</a>
               </sup>
            </span>], increased risk of respiratory infections [
            <span ref-type="bibr" rid="B7">
               <sup>
                  <a href="#B7">7</a>
               </sup>
            </span>], polyhydramnios [
            <span ref-type="bibr" rid="B12">
               <sup>
                  <a href="#B12">12</a>
               </sup>
            </span>], and cholelithiasis [
            <span ref-type="bibr" rid="B13">
               <sup>
                  <a href="#B13">13</a>
               </sup>
            </span>]. Our patient has persistent skin disease and continues to require salt supplementation
            calcium resonium to manage hyperkalemia. Genetic analysis to confirm an ENaC mutation
            was not feasible.
         </p>
         <p>Hyperkalemia is a life-threating condition [
            <span ref-type="bibr" rid="B11">
               <sup>
                  <a href="#B11">11</a>
               </sup>
            </span>]; it requires early recognition and aggressive treatment. Both CAH and PHA1 present
            in the neonatal stage with a similar clinical picture (weight loss, poor feeding,
            dehydration, and lethargy) and laboratory results suggestive of adrenal crisis (hyperkalemia,
            hyponatremia, and acidosis). Treatment with hydrocortisone should be considered in
            all patients with no index case of PHA, especially patients with ambiguous genitalia
            or male patients, because hydrocortisone results in an excellent response in the case
            of CAH. However, it is very important to send blood for 17-hydroxyprogesterone (17-OHP)
            aldosterone, renin, cortisol, and ACTH before starting hydrocortisone. When the patient
            is female with normal genitalia or the response to corticosteroids is poor, resistance
            to aldosterone should always be considered.
         </p>
         <p>Treatment of PHA1 should be considered as an emergency and life-saving measure. This
            comprises adequate rehydration, replacement of salt loss, and correction of hyperkalemia
            and acidosis in the acute phase.
         </p>
         <p>After initial stabilization, potassium exchange resins and salt supplementation are
            the mainstays of treatment. The indomethacin and thiazide diuretics have been tried
            but with limited and variable success rates.
         </p>
      </div>
      <back>
         <div tagxxx="glossary">
            <title>Abbreviations</title>
            <div tagxxx="def-list">
               <div tagxxx="def-item">
                  <div tagxxx="term">PHA1:</div>
                  <div tagxxx="def">
                     <p>Pseudohypoaldosteronism type 1</p>
                  </div>
               </div>
               <div tagxxx="def-item">
                  <div tagxxx="term">CAH:</div>
                  <div tagxxx="def">
                     <p>Congenital adrenal hyperplasia</p>
                  </div>
               </div>
               <div tagxxx="def-item">
                  <div tagxxx="term">ED:</div>
                  <div tagxxx="def">
                     <p>Emergency department</p>
                  </div>
               </div>
               <div tagxxx="def-item">
                  <div tagxxx="term">MTOD:</div>
                  <div tagxxx="def">
                     <p>Multitarget organ defect</p>
                  </div>
               </div>
               <div tagxxx="def-item">
                  <div tagxxx="term"> ENaC:</div>
                  <div tagxxx="def">
                     <p>Epithelial sodium channel.</p>
                  </div>
               </div>
            </div>
         </div>
         <div tagxxx="sec">
            <title>Conflict of Interests</title>
            <p>The authors declare that there is no conflict of interests regarding the publication
               of this paper.
            </p>
         </div>
         <div tagxxx="sec">
            <title>Disclosure</title>
            <p>Yousef I. Marzouk is a medical student at the final year at King Saud bin Abdulaziz
               University for Health Sciences; he helps in reviewing patients' files and writing
               summary and also helps in reviewing the patients' labs and drawing tables.
            </p>
         </div>
         <div tag="ref-list">
            <ul>
               <li tag="ref">
                  <a name="B1"></a>
                  <label>1</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Dillon</span>
                           <span tagx="given-names">M. J.</span>
                        </name>
                        <name>
                           <span tagx="surname">Leonard</span>
                           <span tagx="given-names">J. V.</span>
                        </name>
                        <name>
                           <span tagx="surname">Buckler</span>
                           <span tagx="given-names">J. M.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Pseudohypoaldosteronism</span>
                     <span tagx="source">
                        <i>Archives of Disease in Childhood</i>
                     </span>
                     <span tagx="year">1980</span>
                     <span tagx="volume">55</span>
                     <div tagxxx="issue">6</div>
                     <span tagx="fpage">427</span>
                     <span tagx="lpage">434</span>
                     <span class="pub-id'">[10.1136/adc.55.6.427]</span>
                     <span class="pub-id'">[2-s2.0-0018895343]</span>
                     <span class="pub-id'">[7002056]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B2"></a>
                  <label>2</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Hanukoglu</span>
                           <span tagx="given-names">A.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities
                        with either renal or multiple target organ defects
                     </span>
                     <span tagx="source">
                        <i>The Journal of Clinical Endocrinology &amp; Metabolism</i>
                     </span>
                     <span tagx="year">1991</span>
                     <span tagx="volume">73</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">936</span>
                     <span tagx="lpage">944</span>
                     <span class="pub-id'">[10.1210/jcem-73-5-936]</span>
                     <span class="pub-id'">[2-s2.0-0025789561]</span>
                     <span class="pub-id'">[1939532]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B3"></a>
                  <label>3</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Geller</span>
                           <span tagx="given-names">D. S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zhang</span>
                           <span tagx="given-names">J.</span>
                        </name>
                        <name>
                           <span tagx="surname">Zennaro</span>
                           <span tagx="given-names">M.-C.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal
                        lethality, and phenotypic expression in adults
                     </span>
                     <span tagx="source">
                        <i>Journal of the American Society of Nephrology</i>
                     </span>
                     <span tagx="year">2006</span>
                     <span tagx="volume">17</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">1429</span>
                     <span tagx="lpage">1436</span>
                     <span class="pub-id'">[10.1681/asn.2005111188]</span>
                     <span class="pub-id'">[2-s2.0-33646357245]</span>
                     <span class="pub-id'">[16611713]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B4"></a>
                  <label>4</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Strautnieks</span>
                           <span tagx="given-names">S. S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Thompson</span>
                           <span tagx="given-names">R. J.</span>
                        </name>
                        <name>
                           <span tagx="surname">Gardiner</span>
                           <span tagx="given-names">R. M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Chung</span>
                           <span tagx="given-names">E.</span>
                        </name>
                     </span>
                     <span tagx="article-title">A novel splice–site mutation in the 
                        <i>γ</i> subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type
                        1 families
                     </span>
                     <span tagx="source">
                        <i>Nature Genetics</i>
                     </span>
                     <span tagx="year">1996</span>
                     <span tagx="volume">13</span>
                     <div tagxxx="issue">2</div>
                     <span tagx="fpage">248</span>
                     <span tagx="lpage">250</span>
                     <span class="pub-id'">[10.1038/ng0696-248]</span>
                     <span class="pub-id'">[8640238]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B5"></a>
                  <label>5</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Chang</span>
                           <span tagx="given-names">S. S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Grunder</span>
                           <span tagx="given-names">S.</span>
                        </name>
                        <name>
                           <span tagx="surname">Hanukoglu</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic
                        acidosis, pseudohypoaldosteronism type 1
                     </span>
                     <span tagx="source">
                        <i>Nature Genetics</i>
                     </span>
                     <span tagx="year">1996</span>
                     <span tagx="volume">12</span>
                     <div tagxxx="issue">3</div>
                     <span tagx="fpage">248</span>
                     <span tagx="lpage">253</span>
                     <span class="pub-id'">[10.1038/ng0396-248]</span>
                     <span class="pub-id'">[2-s2.0-13344295074]</span>
                     <span class="pub-id'">[8589714]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B6"></a>
                  <label>6</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Aberer</span>
                           <span tagx="given-names">E.</span>
                        </name>
                        <name>
                           <span tagx="surname">Gebhart</span>
                           <span tagx="given-names">W.</span>
                        </name>
                        <name>
                           <span tagx="surname">Mainitz</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Pollak</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Reichel</span>
                           <span tagx="given-names">G.</span>
                        </name>
                        <name>
                           <span tagx="surname">Scheibenreiter</span>
                           <span tagx="given-names">S.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Sweat glands in pseudohypoaldosteronism</span>
                     <span tagx="source">
                        <i>Der Hautarzt</i>
                     </span>
                     <span tagx="year">1987</span>
                     <span tagx="volume">38</span>
                     <div tagxxx="issue">8</div>
                     <span tagx="fpage">484</span>
                     <span tagx="lpage">487</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B7"></a>
                  <label>7</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Hanukoglu</span>
                           <span tagx="given-names">A.</span>
                        </name>
                        <name>
                           <span tagx="surname">Bistritzer</span>
                           <span tagx="given-names">T.</span>
                        </name>
                        <name>
                           <span tagx="surname">Rakover</span>
                           <span tagx="given-names">Y.</span>
                        </name>
                        <name>
                           <span tagx="surname">Mandelberg</span>
                           <span tagx="given-names">A.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent
                        lower respiratory tract infections mimicking cystic fibrosis
                     </span>
                     <span tagx="source">
                        <i>Journal of Pediatrics</i>
                     </span>
                     <span tagx="year">1994</span>
                     <span tagx="volume">125</span>
                     <div tagxxx="issue">5, part 1</div>
                     <span tagx="fpage">752</span>
                     <span tagx="lpage">755</span>
                     <span class="pub-id'">[7965429]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B8"></a>
                  <label>8</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Robert-Nicoud</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Flahaut</span>
                           <span tagx="given-names">M.</span>
                        </name>
                        <name>
                           <span tagx="surname">Elalouf</span>
                           <span tagx="given-names">J.-M.</span>
                        </name>
                        <etal></etal>
                     </span>
                     <span tagx="article-title">Transcriptome of a mouse kidney cortical collecting duct cell line: effects of aldosterone
                        and vasopressin
                     </span>
                     <span tagx="source">
                        <i>Proceedings of the National Academy of Sciences of the United States of America</i>
                     </span>
                     <span tagx="year">2001</span>
                     <span tagx="volume">98</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">2712</span>
                     <span tagx="lpage">2716</span>
                     <span class="pub-id'">[10.1073/pnas.051603198]</span>
                     <span class="pub-id'">[2-s2.0-0035956993]</span>
                     <span class="pub-id'">[11226305]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B9"></a>
                  <label>9</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Bonny</span>
                           <span tagx="given-names">O.</span>
                        </name>
                        <name>
                           <span tagx="surname">Rossier</span>
                           <span tagx="given-names">B. C.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Disturbances of Na/K balance: pseudohypoaldosteronism revisited</span>
                     <span tagx="source">
                        <i>Journal of the American Society of Nephrology</i>
                     </span>
                     <span tagx="year">2002</span>
                     <span tagx="volume">13</span>
                     <div tagxxx="issue">9</div>
                     <span tagx="fpage">2399</span>
                     <span tagx="lpage">2414</span>
                     <span class="pub-id'">[10.1097/01.asn.0000028641.59030.b2]</span>
                     <span class="pub-id'">[2-s2.0-0036707894]</span>
                     <span class="pub-id'">[12191985]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B10"></a>
                  <label>10</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Riepe</span>
                           <span tagx="given-names">F. G.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Clinical and molecular features of type 1 pseudohypoaldosteronism</span>
                     <span tagx="source">
                        <i>Hormone Research</i>
                     </span>
                     <span tagx="year">2009</span>
                     <span tagx="volume">72</span>
                     <div tagxxx="issue">1</div>
                     <span tagx="fpage">1</span>
                     <span tagx="lpage">9</span>
                     <span class="pub-id'">[10.1159/000224334]</span>
                     <span class="pub-id'">[2-s2.0-67651092155]</span>
                     <span class="pub-id'">[19571553]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B11"></a>
                  <label>11</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Schaefer</span>
                           <span tagx="given-names">T. J.</span>
                        </name>
                        <name>
                           <span tagx="surname">Wolford</span>
                           <span tagx="given-names">R. W.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Disorders of potassium</span>
                     <span tagx="source">
                        <i>Emergency Medicine Clinics of North America</i>
                     </span>
                     <span tagx="year">2005</span>
                     <span tagx="volume">23</span>
                     <div tagxxx="issue">3</div>
                     <span tagx="fpage">723</span>
                     <span tagx="lpage">747</span>
                     <span class="pub-id'">[10.1016/j.emc.2005.03.016]</span>
                     <span class="pub-id'">[2-s2.0-20744460084]</span>
                     <span class="pub-id'">[15982543]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B12"></a>
                  <label>12</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Wong</span>
                           <span tagx="given-names">G. P.</span>
                        </name>
                        <name>
                           <span tagx="surname">Levine</span>
                           <span tagx="given-names">D.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Congenital pseudohypoaldosteronism presenting in utero with acute polyhydramnios</span>
                     <span tagx="source">
                        <i>Journal of Maternal-Fetal Medicine</i>
                     </span>
                     <span tagx="year">1998</span>
                     <span tagx="volume">7</span>
                     <div tagxxx="issue">2</div>
                     <span tagx="fpage">76</span>
                     <span tagx="lpage">78</span>
                     <span class="pub-id'">[10.1002/(sici)1520-6661(199803/04)7:2&lt;76::aid-mfm5&gt;3.0.co;2-l]</span>
                     <span class="pub-id'">[2-s2.0-0031948868]</span>
                     <span class="pub-id'">[9584819]</span>
                  </span>
               </li>
               <li tag="ref">
                  <a name="B13"></a>
                  <label>13</label>
                  <span class="element-citation'">
                     <span class="person-group'">
                        <name>
                           <span tagx="surname">Akkurt</span>
                           <span tagx="given-names">I.</span>
                        </name>
                        <name>
                           <span tagx="surname">Kuhnle</span>
                           <span tagx="given-names">U.</span>
                        </name>
                        <name>
                           <span tagx="surname">Ringenberg</span>
                           <span tagx="given-names">C.</span>
                        </name>
                     </span>
                     <span tagx="article-title">Pseudohypo-aldosteronism and cholelithiasis: coincidence or pathogenetic correlation?</span>
                     <span tagx="source">
                        <i>European Journal of Pediatrics</i>
                     </span>
                     <span tagx="year">1997</span>
                     <span tagx="volume">156</span>
                     <div tagxxx="issue">5</div>
                     <span tagx="fpage">363</span>
                     <span tagx="lpage">366</span>
                     <span class="pub-id'">[10.1007/s004310050615]</span>
                     <span class="pub-id'">[2-s2.0-8244219690]</span>
                     <span class="pub-id'">[9177977]</span>
                  </span>
               </li>
            </ul>
         </div>
      </back>
      <div tagxxx="floats-group">
         <div id="tab1">
            <label>Table 1</label>
            <caption>
               <p>Effect of peritoneal dialysis on blood chemistry.</p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th>Investigation</th>
                     <th>Before peritoneal dialysis</th>
                     <th>After peritoneal dialysis</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Serum sodium</td>
                     <td>122 mmol/L</td>
                     <td>134 mmol/L (135–144)</td>
                  </tr>
                  <tr>
                     <td>Serum chloride</td>
                     <td>95 mmol/L</td>
                     <td>92 mmol/L (101–111)</td>
                  </tr>
                  <tr>
                     <td>Serum potassium</td>
                     <td>9.24 mmol/L</td>
                     <td>6.42 mmol/L (3.5–4.9)</td>
                  </tr>
                  <tr>
                     <td>Serum bicarbonate</td>
                     <td>11 mmol/L</td>
                     <td>25 mmol/L (23–31)</td>
                  </tr>
                  <tr>
                     <td>Blood urea</td>
                     <td>7.1 mmol/L</td>
                     <td>6.4 mmol/L (1.9–5.7)</td>
                  </tr>
                  <tr>
                     <td>Serum creatinine</td>
                     <td>64 umol/L</td>
                     <td>71 umol/L (50–74)</td>
                  </tr>
               </tbody>
            </table>
         </div>
         <div id="tab2">
            <label>Table 2</label>
            <caption>
               <p>Results of hormonal studies.</p>
            </caption>
            <table>
               <thead>
                  <tr>
                     <th>Investigation</th>
                     <th>Results (normal range)</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Serum renin activity</td>
                     <td> 28.6 ng/mL/h (0.1–3.1) </td>
                  </tr>
                  <tr>
                     <td>Serum aldosterone</td>
                     <td> 145 ng/dL (3–16)</td>
                  </tr>
                  <tr>
                     <td>Serum cortisol</td>
                     <td> 87.9 ug/dL (2.3–11.9)</td>
                  </tr>
               </tbody>
            </table>
         </div>
      </div>
   </article>
</html>